This website is for information purposes only. Use of our website is subject to your agreement to our disclaimer and terms and conditions. By closing (click "I agree") or leaving this box, you signify your agreement to these.
The gene SPT1 promotes the production of sphingolipid, plays an important role to suppress the onset of non-allergic asthma. The SSHD – STP molecule targets SPT1 gene as a first step in alleviation and avoidance of non-allergic asthma.
What does SPT1 do?
SPT1 promotes the production of sphingolipid.
Scientists at Columbia University, New York [1] have discovered a completely new type of asthma.
Asthma is a very common cause of breathing difficulty. It can have serious consequences. It is understood that asthma can be caused by an allergic reaction in the airways to airborne particles such as pollen. The allergic reaction results in acute inflammation and swelling of the airway tissues so that breathing is impaired. The inflammatory allergic reaction involves an unusual type of antibody called IgE that is bound to mast cells in the airways.
Corticosteroids reduce inflammation. That is why inhalation of anti-inflammatory compounds such as corticosteroids is very effective in relief of asthma. Unfortunately, almost half of asthma sufferers do not respond to corticosteroid treatment. The reason why has been unclear. Now, this newly discovered form of asthma explains why many sufferers do not respond to anti-inflammatory or corticosteroid therapy. The newly discovered form of non-inflammatory asthma is due to a deficiency of a cell membrane component called sphingolipid in cells that line the airways. Activity of the gene SPT1 has been shown by Dr. Worgall and colleagues [1] to play an important role of the production of sphingolipid and suppress the onset of non-allergic asthma.